US EditionENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)
Summary by ophthalmologytimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
ENTOD Pharmaceuticals receives CDSCO approval for paediatric myopia treatment - Express Pharma
ENTOD Pharmaceuticals has announced that it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for a new ophthalmic formulation designed to slow the progression of myopia in children aged 6 to 12 years. This marks the first global regulatory approval for this specific treatment strength in paediatric eye care. The approval follows the completion of Phase 3 clinical trials conducted in India and a de…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
